Madrigal (MDGL) | Stock Overview & Key Data
Madrigal Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $415.80 on January 28, 2013
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Madrigal MDGL | 6.28B Mid-cap | -4.21% | 2.60% | -5.04% | -13.76% | -8.37% | 1.16% | 317.94% | 170.00% |
| Vertex VRTX | 114.06B Large-cap | 3.14% | 4.53% | -1.27% | 13.16% | 14.93% | -6.00% | 56.88% | 55.98% |
| Regeneron REGN | 55.27B Large-cap | 2.40% | 5.82% | -1.63% | -25.33% | -23.41% | -51.08% | -11.43% | -16.45% |
| Blueprint Medicines BPMC | 8.29B Mid-cap | 0.05% | 0.34% | 62.08% | 41.67% | 47.25% | 9.02% | 139.78% | 65.31% |
| Roivant Sciences ROIV | 7.82B Mid-cap | -0.73% | -1.99% | 19.60% | -1.45% | -10.10% | -5.37% | 151.52% | 8.27% |
| Bio-Techne TECH | 7.92B Mid-cap | 1.15% | 5.61% | 7.93% | -29.94% | -26.30% | -33.33% | -40.13% | -26.31% |
Madrigal Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Madrigal would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
What is MDGL's 52-week high and low?
In the last 52 weeks, Madrigal reached a high of $377.46 (on N/A) and a low of $200.63 (on October 23, 2024).
What is the market cap and P/E ratio for MDGL?
Curious about Madrigal's size and valuation? Its market capitalization stands at 6.28B. When it comes to valuation, the P/E ratio (trailing twelve months) is -13.01, and the forward P/E (looking ahead) is N/A.
Does MDGL pay dividends? If so, what's the yield?
As for dividends, Madrigal isn't currently offering a significant yield, or that specific data isn't available right now.
Who are Madrigal's main competitors or similar companies to consider before investing?
When looking at Madrigal, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
| Company | Mkt Cap | Sector | Industry | 1Y Return | 3Y Return |
|---|---|---|---|---|---|
| Vertex VRTX | 114.06B | Healthcare | Biotechnology | -6.00% | 56.88% |
| Regeneron REGN | 55.27B | Healthcare | Biotechnology | -51.08% | -11.43% |
| Blueprint Medicines BPMC | 8.29B | Healthcare | Biotechnology | 9.02% | 139.78% |
| Roivant Sciences ROIV | 7.82B | Healthcare | Biotechnology | -5.37% | 151.52% |
| Bio-Techne TECH | 7.92B | Healthcare | Biotechnology | -33.33% | -40.13% |
For a more comprehensive list, please see the Peer Performance Comparison table on this page.
What are the key financial health indicators for Madrigal Pharmaceuticals Inc.? (e.g., ROE, Debt/Equity)
To get a sense of Madrigal's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is N/A, the Debt to Equity ratio from the most recent quarter is N/A, and its Gross Profit Margin stands at N/A.
What is the recent revenue and earnings growth for MDGL?
Looking at Madrigal's growth, its revenue over the trailing twelve months (TTM) was N/A. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.
How much of MDGL stock is held by insiders and institutions?
Wondering who owns Madrigal stock? Company insiders (like executives and directors) hold about N/A of the shares, while institutional investors (such as mutual funds and pension funds) own approximately N/A.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.